U.S., Sept. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07187167) titled 'Efficacy and Safety of the RD Regimen(Lenalidomide, Dexamethasone) for Rosai-Dorfman Disease' on Aug. 25.
Brief Summary: In patients with Rosai-Dorfman disease (RDD), a treatment regimen of lenalidomide combined with dexamethasone is planned to be used.
Study Start Date: April 12
Study Type: INTERVENTIONAL
Condition:
Rosai-Dorfman Disease
Intervention:
DRUG: Lenalidomide
The combination therapy period consists of 12 cycles: Lenalidomide: 25mg, orally, D1-21, every 28 days per cycle. Combined with Dexamethasone: 40mg, orally, D1, 8, 15, 22, every 28 days per cycle. The single-agent maintenance period consists of 12 cycles: Le...